Gerard Chamberlin, MD
Internal Medicine · Mesa, AZNPI 1750503124
Payments from drug & device makers
Across 113 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$215
- AstraZeneca$194
- Sanofi-aventis U.S. LLC$190
- GSK$181
- Sunovion Pharmaceuticals Inc.$141
- Regeneron Healthcare Solutions, Inc.$139
- plus $826 from 18 others
What the payments were for
- Food & beverage$1,73692%
- Education$1297%
- Other$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $215 |
| AstraZeneca | 12 | $194 |
| Sanofi-aventis U.S. LLC | 13 | $190 |
| GSK | 12 | $181 |
| Sunovion Pharmaceuticals Inc. | 10 | $141 |
| Regeneron Healthcare Solutions, Inc. | 1 | $139 |
| Astellas Pharma US Inc | 3 | $124 |
| Novo Nordisk | 7 | $93 |
| Amgen | 6 | $91 |
| Lilly USA, LLC | 6 | $84 |
| Merck | 5 | $72 |
| Pfizer | 4 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $46 |
| Johnson & Johnson | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Seqirus USA Inc | 2 | $28 |
| Novartis | 2 | $27 |
| AbbVie | 1 | $22 |
| Abbott | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Circassia Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVKEEZA$139
How this compares
$1,886 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 153 | $208,351 |
| OzempicSemaglutide | 110 | $198,045 |
| JardianceEmpagliflozin | 89 | $112,283 |
| FarxigaDapagliflozin Propanediol | 61 | $75,443 |
| MyrbetriqMirabegron | 49 | $53,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $51,602 |
| RybelsusSemaglutide | 22 | $49,202 |
| TrulicityDulaglutide | 23 | $42,957 |
| JanuviaSitagliptin Phosphate | 35 | $41,030 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 98 | $30,705 |
| Spiriva RespimatTiotropium Bromide | 36 | $30,436 |
| XareltoRivaroxaban | 32 | $30,057 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $29,949 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $28,507 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $22,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $93 | $247,248132 claims |
| PfizerEliquis | $55 | $208,351153 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Stiolto Respimat, Tradjenta | $215 | $195,337178 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta | $181 | $96,878161 claims |
| AstraZenecaFarxiga, Symbicort | $194 | $83,98479 claims |
| Astellas Pharma US IncMyrbetriq | $124 | $53,51449 claims |
| Lilly USA, LLCTrulicity | $84 | $42,95723 claims |
| MerckJanuvia | $72 | $41,03035 claims |
| Johnson & JohnsonXarelto | $43 | $30,05732 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $190 | $29,94919 claims |
| AmgenProlia | $91 | $22,10513 claims |
| AbbVieLinzess | $22 | $20,40920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Mesa
- Yessica SachdevaMesa$13.7M
- Tami BruceMesa$976K
- Ali ImranMesa$240K
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.